↓ Skip to main content

Cochrane Database of Systematic Reviews

Natalizumab for relapsing remitting multiple sclerosis

Overview of attention for article published in Cochrane database of systematic reviews, October 2011
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
policy
1 policy source
twitter
13 X users
facebook
1 Facebook page
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
87 Dimensions

Readers on

mendeley
353 Mendeley
Title
Natalizumab for relapsing remitting multiple sclerosis
Published in
Cochrane database of systematic reviews, October 2011
DOI 10.1002/14651858.cd007621.pub2
Pubmed ID
Authors

Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Silvana Simi, Silvia Minozzi, Carlo Di Pietrantonj, Ian Galea

Abstract

Natalizumab (NTZ) (Tysabri(®)) is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier, thus reducing inflammation in central nervous system, and has been approved worldwide for the treatment of relapsing-remitting multiple sclerosis (RRMS).

X Demographics

X Demographics

The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 353 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 <1%
Brazil 2 <1%
Chile 1 <1%
Italy 1 <1%
Sri Lanka 1 <1%
United Kingdom 1 <1%
Unknown 345 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 55 16%
Student > Ph. D. Student 35 10%
Student > Bachelor 35 10%
Researcher 34 10%
Student > Doctoral Student 22 6%
Other 57 16%
Unknown 115 33%
Readers by discipline Count As %
Medicine and Dentistry 110 31%
Psychology 24 7%
Nursing and Health Professions 23 7%
Agricultural and Biological Sciences 11 3%
Pharmacology, Toxicology and Pharmaceutical Science 10 3%
Other 44 12%
Unknown 131 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2020.
All research outputs
#1,150,287
of 25,461,852 outputs
Outputs from Cochrane database of systematic reviews
#2,361
of 12,090 outputs
Outputs of similar age
#4,912
of 144,905 outputs
Outputs of similar age from Cochrane database of systematic reviews
#14
of 131 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,090 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.2. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 144,905 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 131 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.